vs
克瑞（CR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是克瑞的1.1倍（$772.1M vs $696.4M），Revvity净利率更高（12.7% vs 9.6%，领先3.1%），克瑞同比增速更快（24.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-40.2M），过去两年克瑞的营收复合增速更高（14.8% vs 9.0%）
克瑞是总部位于美国康涅狄格州斯坦福德的工业产品企业，1855年由理查德·泰勒·克兰创立。公司曾是美国领先卫浴配件制造商，1990年出售该业务板块，1960年起逐步转型为多元化控股集团，当前核心业务涵盖航空航天与电子、工程材料、流体处理、控制系统四大板块，服务化工等多个行业领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$696.4M
营收增速更快
CR
高出19.0%
5.9%
净利率更高
RVTY
高出3.1%
9.6%
自由现金流更多
RVTY
多$202.0M
$-40.2M
两年增速更快
CR
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $696.4M | $772.1M |
| 净利润 | $67.1M | $98.4M |
| 毛利率 | 40.4% | — |
| 营业利润率 | 14.4% | 14.5% |
| 净利率 | 9.6% | 12.7% |
| 营收同比 | 24.9% | 5.9% |
| 净利润同比 | -37.3% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRRVTY
| Q1 26 | $696.4M | — | ||
| Q4 25 | $581.0M | $772.1M | ||
| Q3 25 | $589.2M | $698.9M | ||
| Q2 25 | $577.2M | $720.3M | ||
| Q1 25 | $557.6M | $664.8M | ||
| Q4 24 | $544.1M | $729.4M | ||
| Q3 24 | $548.3M | $684.0M | ||
| Q2 24 | $528.6M | $691.7M |
净利润CRRVTY
| Q1 26 | $67.1M | — | ||
| Q4 25 | $81.7M | $98.4M | ||
| Q3 25 | $91.4M | $46.7M | ||
| Q2 25 | $86.4M | $53.9M | ||
| Q1 25 | $107.1M | $42.2M | ||
| Q4 24 | $81.0M | $94.6M | ||
| Q3 24 | $77.3M | $94.4M | ||
| Q2 24 | $71.6M | $55.4M |
毛利率CRRVTY
| Q1 26 | 40.4% | — | ||
| Q4 25 | 41.6% | — | ||
| Q3 25 | 42.7% | 53.6% | ||
| Q2 25 | 42.0% | 54.5% | ||
| Q1 25 | 42.6% | 56.5% | ||
| Q4 24 | 40.9% | — | ||
| Q3 24 | 41.4% | 56.3% | ||
| Q2 24 | 40.0% | 55.7% |
营业利润率CRRVTY
| Q1 26 | 14.4% | — | ||
| Q4 25 | 17.5% | 14.5% | ||
| Q3 25 | 20.1% | 11.7% | ||
| Q2 25 | 17.8% | 12.6% | ||
| Q1 25 | 18.1% | 10.9% | ||
| Q4 24 | 15.8% | 16.3% | ||
| Q3 24 | 18.1% | 14.3% | ||
| Q2 24 | 16.9% | 12.4% |
净利率CRRVTY
| Q1 26 | 9.6% | — | ||
| Q4 25 | 14.1% | 12.7% | ||
| Q3 25 | 15.5% | 6.7% | ||
| Q2 25 | 15.0% | 7.5% | ||
| Q1 25 | 19.2% | 6.4% | ||
| Q4 24 | 14.9% | 13.0% | ||
| Q3 24 | 14.1% | 13.8% | ||
| Q2 24 | 13.5% | 8.0% |
每股收益（稀释后）CRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.40 | $0.86 | ||
| Q3 25 | $1.56 | $0.40 | ||
| Q2 25 | $1.47 | $0.46 | ||
| Q1 25 | $1.83 | $0.35 | ||
| Q4 24 | $1.37 | $0.77 | ||
| Q3 24 | $1.33 | $0.77 | ||
| Q2 24 | $1.23 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $355.4M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $2.1B | $7.3B |
| 总资产 | $4.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.57× | — |
8季度趋势，按日历期对齐
现金及短期投资CRRVTY
| Q1 26 | $355.4M | — | ||
| Q4 25 | $506.5M | $919.9M | ||
| Q3 25 | $388.2M | $931.4M | ||
| Q2 25 | $332.2M | $991.8M | ||
| Q1 25 | $435.1M | $1.1B | ||
| Q4 24 | $306.7M | $1.2B | ||
| Q3 24 | $258.2M | $1.2B | ||
| Q2 24 | $229.3M | $2.0B |
总债务CRRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $247.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CRRVTY
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $7.3B | ||
| Q3 25 | $2.0B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.5B | $7.9B |
总资产CRRVTY
| Q1 26 | $4.1B | — | ||
| Q4 25 | $3.9B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B |
负债/权益比CRRVTY
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-40.2M | $161.8M |
| 自由现金流率自由现金流/营收 | -5.8% | 21.0% |
| 资本支出强度资本支出/营收 | 1.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $361.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $205.8M | $182.0M | ||
| Q3 25 | $130.2M | $138.5M | ||
| Q2 25 | $105.0M | $134.3M | ||
| Q1 25 | $-46.2M | $128.2M | ||
| Q4 24 | $202.0M | $174.2M | ||
| Q3 24 | $75.4M | $147.9M | ||
| Q2 24 | $51.3M | $158.6M |
自由现金流CRRVTY
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $196.0M | $161.8M | ||
| Q3 25 | $116.8M | $120.0M | ||
| Q2 25 | $88.9M | $115.5M | ||
| Q1 25 | $-60.4M | $112.2M | ||
| Q4 24 | $188.2M | $149.8M | ||
| Q3 24 | $67.3M | $125.6M | ||
| Q2 24 | $44.6M | $136.6M |
自由现金流率CRRVTY
| Q1 26 | -5.8% | — | ||
| Q4 25 | 33.7% | 21.0% | ||
| Q3 25 | 19.8% | 17.2% | ||
| Q2 25 | 15.4% | 16.0% | ||
| Q1 25 | -10.8% | 16.9% | ||
| Q4 24 | 34.6% | 20.5% | ||
| Q3 24 | 12.3% | 18.4% | ||
| Q2 24 | 8.4% | 19.7% |
资本支出强度CRRVTY
| Q1 26 | 1.5% | — | ||
| Q4 25 | 1.7% | 2.6% | ||
| Q3 25 | 2.3% | 2.6% | ||
| Q2 25 | 2.8% | 2.6% | ||
| Q1 25 | 2.5% | 2.4% | ||
| Q4 24 | 2.5% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 1.3% | 3.2% |
现金转化率CRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.52× | 1.85× | ||
| Q3 25 | 1.42× | 2.97× | ||
| Q2 25 | 1.22× | 2.49× | ||
| Q1 25 | -0.43× | 3.03× | ||
| Q4 24 | 2.49× | 1.84× | ||
| Q3 24 | 0.98× | 1.57× | ||
| Q2 24 | 0.72× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CR
| Process Flow Technologies | $378.1M | 54% |
| Aerospace & Advanced Technologies | $318.3M | 46% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
